Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Galectin Therapeutic (NQ: GALT)
4.630 USD  -0.120 (-2.53%)
Official Closing Price  /  Updated: 4:00 PM EST, Jan 22, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 133,827
Open 4.800
Bid (Size) 4.120 (1)
Ask (Size) 5.000 (3)
Prev. Close 4.750
Today's Range 4.580 - 4.800
52wk Range 3.100 - 9.490
Shares Outstanding 37,740,647
Dividend Yield N/A
Performance
YTD
+19.95%
+19.95%
1 Month
+25.82%
+25.82%
3 Month
-0.86%
-0.86%
6 Month
-14.73%
-14.73%
1 Year
-11.30%
-11.30%
Top News
More News
Galectin Therapeutics’ Largest Institutional Shareholder Converts Existing Series B Preferred Stock Into Common Stock Streamlining Its Capital Structure
Board Chairman Richard Uihlein extends existing $10 million unsecured line of credit for two additional years Read More
from GlobeNewswire News Releases
Galectin Therapeutics Announces Extension of $10 Million Line Credit
Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that its $10 million unsecured line of credit entered into on December... Read More
from GlobeNewswire News Releases
More News
Read More
New Research: Key Drivers of Growth for Martin Midstream Partners, Galectin Therapeutics, Mountain Province Diamonds, MINDBODY, Pareteum, and Pieris Pharmaceuticals — Factors of Influence, Major Initi
from GlobeNewswire News Releases
Galectin Therapeutics to Present at the 2nd Annual Anti-Fibrotic Drug Development Summit
from GlobeNewswire News Releases
Galectin Therapeutics Reports 2018 Third Quarter Financial Results and Provides Business Update
from GlobeNewswire News Releases
Data Collected by Exalenz Bioscience in Galectin Therapeutics’ Phase 2 NASH-CX Trial of GR-MD-02 to Be Presented at AASLD Annual Meeting
from GlobeNewswire News Releases
Galectin Therapeutics to Participate in The ROTH Capital Battle of the NASH Thrones Investment Conference
from GlobeNewswire News Releases
Galectin Therapeutics to Present at The ROTH Capital Battle of the NASH Thrones Investment Conference
from GlobeNewswire News Releases
Market Trends Toward New Normal in Altra Industrial Motion, IDEXX Laboratories, BioTelemetry, Galectin Therapeutics, NETGEAR, and Merck & Co. — Emerging Consolidated Expectations, Analyst Ratings
from GlobeNewswire News Releases
How The Parts Add Up: SPSM Headed For $35
category ETFs
from ETF Channel
Galectin Therapeutics Breaks Above 200-Day Moving Average - Bullish for GALT
category Stocks
from Market News Video
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.